{"denoms":[{"counts":[{"groupId":"BG000","value":"253"},{"groupId":"BG001","value":"249"},{"groupId":"BG002","value":"502"}],"units":"Participants"}],"groups":[{"description":"Participants with rCC/mCC were administered tisotumab vedotin 2.0 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once every 3 weeks (Q3W).","id":"BG000","title":"Tisotumab Vedotin"},{"description":"Participants with rCC/mCC were treated with investigator's choice of chemotherapy which included either topotecan 1 or 1.25 milligram per meter square \\[mg/m\\^2\\] IV on Days 1 to 5, every 21 days or vinorelbine 30 mg/m\\^2 IV on Days 1 and 8, every 21 days or gemcitabine 1000 mg/m\\^2 IV on Days 1 and 8, every 21 days or irinotecan 100 or 125 mg/m\\^2 IV weekly for 28 days, every 42 days or pemetrexed 500 mg/m\\^2 on Day 1, every 21 days.","id":"BG001","title":"Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.8","value":"51.9"},{"groupId":"BG001","spread":"11.6","value":"51.0"},{"groupId":"BG002","spread":"11.7","value":"51.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"253"},{"groupId":"BG001","value":"249"},{"groupId":"BG002","value":"502"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"122"},{"groupId":"BG001","value":"122"},{"groupId":"BG002","value":"244"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"90"},{"groupId":"BG001","value":"90"},{"groupId":"BG002","value":"180"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"14"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"10"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"36"}],"title":"Not Reported"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"14"}],"title":"Unknown"}],"title":"Race"}],"description":"Race is reported.","paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"176"},{"groupId":"BG001","value":"177"},{"groupId":"BG002","value":"353"}],"title":"Not of Hispanic or Latino/a, or Spanish Origin"},{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"102"}],"title":"Hispanic or Latino/a, or of Spanish Origin"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"36"}],"title":"Not Reported"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"}],"title":"Unknown"}],"title":"Ethinicity"}],"description":"Ethnicity is reported.","paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-treat (ITT) analysis set included all randomized participants. Participants were included in the treatment group assigned at randomization regardless of any actual treatment received."}